Fig. 1 · Structure

Documents & Downloads

P505-15 (PRT062607, BIIB057)

Cat. No. A11952 CAS 1370261-96-3

Syk inhibitor

P505-15 (also known as PRT062607) is a novel, highly selective, and orally bioavailable small molecule SYK inhibitor (SYK IC(50) = 1 nM) with anti-SYK activity that is at least 80-fold greater than its affinity for other kinases.

In Stock

Publications for P505-15

1 publication citing this product

  1. Li T, .et al. , Oncogene, 2018, Nov;37(47):6180-6194 PMID: 30013190

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

In Ramos B-cell lymphoma cells, P505-15 reduced BCR-induced SYK autophosphorylation and downstream ERK/AKT phosphorylation. The Lyn-associated SYK Y352 signal was not fully inhibited. These cellular results concern the reported (1R,2S) acetate material and do not establish potency or lot equivalence for the catalog free base. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Cellular Effect

Cell Line Activity Value Description Reference
Bone marrow cell IC50 5853 nM Inhibition of IL3 dependent proliferation in C57/B16 mouse bone marrow cells using [3H]thymidine by liquid scintillation counting [PMID: 24726806]
Bone marrow cell IC50 5853 nM Cytotoxicity against C57BL/6 mouse bone marrow cells assessed as growth inhibition preincubated for 4 days followed by [3H]-thymidine addition measured after 5 hrs by betaplate counting analysis [PMID: 25633741]
CHO IC50 8600 nM Inhibition of human ERG expressed in CHO cells by automated Qpatch clamp assay [PMID: 25633741]
Jurkat IC50 1805 nM Inhibition of ZAP70 in anti-CD3 stimulated human Jurkat T cells assessed as SLP76 phosphorylation at Y128 preincubated for 30 mins followed by anti-CD3 stimulation measured after 2 mins by FACS analysis [PMID: 25633741]
Ramos IC50 178 nM Inhibition of Syk in anti IgM-stimulated human Ramos cells assessed as BLNK phosphorylation by cellular assay [PMID: 24726806]

In Vitro Studies

PRT062607 inhibited BCR-mediated B-cell activation in RA whole blood ex vivo. Samples from patients receiving stable methotrexate had a lower IC50 than samples from patients without methotrexate. The nonrandomized comparison supports context-dependent inhibitor responses, without establishing clinical combination efficacy; the tested salt form was unspecified. [2]

BCR-induced signaling in Ramos cells

Cell-based study · Human Ramos B-cell lymphoma cells, stimulated and unstimulated controls. [1]

P505-15 reduced SYK Y525/526 autophosphorylation and downstream ERK Y204/AKT S473 phosphorylation. The upstream Lyn-associated SYK Y352 signal was incompletely inhibited and did not show a wholly concentration-dependent response.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Inhibition of BCR-induced ERK Y204 and AKT S473 phosphorylationCellular signaling concentration response Approximately 50 nM for half-maximal inhibition; complete inhibition reported at 250 nM[1]
Specificity control: SYK Y352 phosphorylationQualitative signaling control Incomplete inhibition; effect not entirely concentration-dependent[1]

Literature-Reported Treatment Conditions

Treatment concentration
2 μM for immunoblot; 0.02–2 μM in Figure 1B phospho-flow
Exposure duration
30-minute pretreatment; 30-minute anti-IgM stimulation for immunoblot, 10-minute stimulation for phospho-flow
Method
Anti-IgM stimulation (1 μg/mL); immunoblot and intracellular phospho-flow
Vehicle
Vehicle control; solvent identity not specified for this assay
Reported limits
Flow readout n = 3, mean + S.D.; number of independent immunoblots not specified in read caption.
Methods and source locations

Compound reported in the paper: P505-15 (PRT062607); Compound label in the paper: Literature material

Results describe the literature acetate material, not validation of the catalog free base or an Adooq lot. No salt dose conversion performed.

Figure 1A–C and caption; Methods: SYK Autophosphorylation and Intracellular Phospho-flow Cytometry; first Results subsection

Inhibition of BCR-induced ERK Y204 and AKT S473 phosphorylation: Intracellular phospho-flow; MFI normalized to vehicle control, mean + S.D., n = 3 — Figure 1A–C and caption; Methods: SYK Autophosphorylation and Intracellular Phospho-flow Cytometry; first Results subsection

Specificity control: SYK Y352 phosphorylation: Phospho-flow with stimulated vehicle and unstimulated controls — Figure 1A–C and caption; Methods: SYK Autophosphorylation and Intracellular Phospho-flow Cytometry; first Results subsection

Ex vivo B-cell activation in RA whole blood

Cell-based study · Whole blood from 30 RA patients (32 samples because two patients donated twice); healthy-donor comparison. MTX comparison: 18 samples with stable MTX and 14 without. [2]

PRT062607 inhibited anti-IgD-induced CD69 upregulation. Overall B-cell IC50 values were similar in RA and healthy blood, but higher levels of inhibition were harder to achieve in RA. Lower IC50 was associated with stable MTX therapy; patient treatment was not randomized.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Suppression of BCR-mediated B-cell CD69 upregulation by background MTX statusIC50 MTX: 224 nmol/L (95% CI 178–272); no MTX: 385 nmol/L (95% CI 300–492)[2]
Overall B-cell activation inhibition in healthy versus RA whole bloodIC50 Healthy: 254 nM; RA: 248 nM[2]

Literature-Reported Treatment Conditions

Treatment concentration
Concentration-response series through 4 μmol/L shown in Figures 1–2
Exposure duration
30-minute inhibitor pretreatment, then 16-hour anti-IgD stimulation
Method
Ex vivo whole-blood flow cytometry for CD69 on B cells
Vehicle
Control-normalized response; vehicle solvent identity not specified
Co-treatment
Stable background MTX was an observed patient covariate, not a randomized added ex vivo treatment.
Reported limits
Full MTX regimen and individual inhibitor curve dose series are not supplied here. Counts differ by assay; samples are not all independent patients.
Methods and source locations

Compound reported in the paper: P505-15 (PRT062607); Compound label in the paper: Literature material

Ex vivo results for the reported PRT062607 material; form equivalence to the catalog free base remains unverified.

Figure 1B and Figure 2C with captions; Methods: Study design and patient enrollment, Human whole blood ex vivo immune function tests, Statistical analysis; Results: Patient characteristics and MTX uniquely restores PRT062607 inhibitory potency

Suppression of BCR-mediated B-cell CD69 upregulation by background MTX status: Figure 2C nonlinear logistic fit; mean ± SEM curves; n = 18 and 14 samples, respectively — Figure 1B and Figure 2C with captions; Methods: Study design and patient enrollment, Human whole blood ex vivo immune function tests, Statistical analysis; Results: Patient characteristics and MTX uniquely restores PRT062607 inhibitory potency

Overall B-cell activation inhibition in healthy versus RA whole blood: Figure 1B; n = 17 healthy and 31 RA assay samples; mean ± SEM — Figure 1B and caption; Results: Syk-independent mechanism(s) influence B-cell activation

In Vivo Studies

P505-15 acetate reduced Ramos xenograft tumor weights when oral treatment began on implantation day. A separate experiment reported no effect on progression when treatment began in established tumors. The positive result therefore supports prevention/engraftment-phase activity rather than established-tumor efficacy; the prophylactic endpoint timing differs between the caption and Methods. [1]

In established G6PI-induced arthritis in mice, PRT062607 alone did not stop clinical progression. Combined treatment with tofacitinib improved clinical scores and joint histology more strongly, including protection against bone and cartilage damage. This is a combination result for the reported literature materials, not evidence of equivalent monotherapy or human efficacy. [3]

P505-15 begun at Ramos xenograft implantation

Animal study · NOD/SCID mice with subcutaneous Ramos xenografts; n = 15 randomized per group in Methods, n = 13–15 evaluated in Figure 3. [1]

Treatment beginning on implantation day reduced endpoint tumor weights versus vehicle. This design supports prevention/engraftment-phase activity; it does not demonstrate regression of established tumors.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Excised endpoint tumor weight versus vehicleTumor weight comparison Significantly lower at each tested dose; 10 mg/kg: P = 0.0016; 15 mg/kg: P = 0.0001; 20 mg/kg: P = 0.0071[1]

Conditions shared by the study groups

Route
Oral gavage
Frequency
Twice daily
Treatment course
Begun on implantation day; 4-week Figure 3 / 5-week Methods discrepancy
Vehicle
0.5% methylcellulose in water
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
10 mg/kg P505-15
10 mg/kg
Vehicle-treated xenograft miceReduced endpoint tumor weight; P = 0.0016 versus vehicle.[1]
15 mg/kg P505-15
15 mg/kg
Vehicle-treated xenograft miceReduced endpoint tumor weight; P = 0.0001 versus vehicle.[1]
20 mg/kg P505-15
20 mg/kg
Vehicle-treated xenograft miceReduced endpoint tumor weight; P = 0.0071 versus vehicle.[1]
10 mg/kg P505-15
Model: NOD/SCID mice with subcutaneous Ramos xenografts; n = 15 randomized per group in Methods, n = 13–15 evaluated in Figure 3.
Reported limits: Reported literature acetate; no dose conversion.
15 mg/kg P505-15
Model: NOD/SCID mice with subcutaneous Ramos xenografts; n = 15 randomized per group in Methods, n = 13–15 evaluated in Figure 3.
Reported limits: Reported literature acetate; no dose conversion.
20 mg/kg P505-15
Model: NOD/SCID mice with subcutaneous Ramos xenografts; n = 15 randomized per group in Methods, n = 13–15 evaluated in Figure 3.
Reported limits: Reported literature acetate; no dose conversion.
Methods and source locations

Compound reported in the paper: P505-15 (PRT062607); Compound label in the paper: Literature material

Results describe the literature acetate material, not validation of the catalog free base or an Adooq lot. No salt dose conversion performed.

Methods: Xenograft Studies; Results: SYK Inhibition Protects against Tumor Formation in a Mouse Xenograft Model; Figure 3A and caption

Excised endpoint tumor weight versus vehicle: Figure 3A individual animals (n = 13–15/group); Methods specify t-test — Methods: Xenograft Studies; Results: SYK Inhibition Protects against Tumor Formation in a Mouse Xenograft Model; Figure 3A and caption

10 mg/kg P505-15 · Methods: Xenograft Studies; Results: SYK Inhibition Protects against Tumor Formation in a Mouse Xenograft Model; Figure 3A and caption

15 mg/kg P505-15 · Methods: Xenograft Studies; Results: SYK Inhibition Protects against Tumor Formation in a Mouse Xenograft Model; Figure 3A and caption

20 mg/kg P505-15 · Methods: Xenograft Studies; Results: SYK Inhibition Protects against Tumor Formation in a Mouse Xenograft Model; Figure 3A and caption

Reported negative result in established Ramos tumors

Animal study · Ramos xenograft-bearing mice; treatment initiated at approximately 200 mg estimated tumor size. [1]

In a separate randomized vehicle-controlled experiment, P505-15 did not affect progression of established tumors over 10 days. The authors suggest that their prophylactic result may reflect inhibition of engraftment.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Established tumor progression versus oral vehicleAuthor-reported qualitative negative result P505-15 did not affect tumor progression[1]

Conditions shared by the study groups

Route
Oral treatment
Treatment course
10 days; treatment initiated when tumor size was estimated by caliper to be approximately 200 mg.
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
P505-15 in established Ramos tumorsMice randomized to oral vehicle or P505-15 treatment; vehicle composition not reported for this separate experiment.P505-15 did not affect tumor progression under these conditions (author-reported qualitative result; data not shown).[1]
P505-15 in established Ramos tumors
Model: Ramos xenograft-bearing mice; treatment initiated at approximately 200 mg estimated tumor size.
Reported limits: Dose, dosing frequency, sample size, vehicle composition, quantitative response and statistical comparison are not reported for this separate experiment. No prophylactic-study conditions imported.
Methods and source locations

Compound reported in the paper: P505-15 (PRT062607); Compound label in the paper: Literature material

Results describe the literature acetate material, not validation of the catalog free base or an Adooq lot. No salt dose conversion performed.

Results: SYK Inhibition Protects against Tumor Formation in a Mouse Xenograft Model; paragraph following Tables 1–2, separate established-tumor experiment (data not shown)

Established tumor progression versus oral vehicle: Tumor size estimated by caliper; separate experiment, data not shown — Results: SYK Inhibition Protects against Tumor Formation in a Mouse Xenograft Model; paragraph following Tables 1–2, separate established-tumor experiment (data not shown)

P505-15 in established Ramos tumors · Results: SYK Inhibition Protects against Tumor Formation in a Mouse Xenograft Model; paragraph following Tables 1–2, separate established-tumor experiment (data not shown)

Single and combined kinase inhibition in established arthritis

Animal study · Male DBA/1 mice with G6PI-induced chronic arthritis following regulatory T-cell depletion; Figure 2 caption reports 3–7 mice/group. [3]

PRT062607 alone did not arrest clinical progression. Combined PRT062607 and tofacitinib improved clinical scores and joint histology more strongly than either single treatment. The combination result must not be assigned to PRT062607 alone.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Clinical arthritis progression after treatment of established diseaseClinical score time course Single SYK inhibition did not stop progression; combined JAK/SYK inhibition progressively decreased clinical scores[3]
Tarsal joint inflammation and structural damageHistopathology Single inhibitors reduced inflammation; only dual JAK/SYK inhibition prevented bone and cartilage damage in this comparison[3]

Conditions shared by the study groups

Route
Oral
Frequency
Once daily
Treatment course
Day 12 through day-31 sampling
Vehicle
Water
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
PRT062607 alone
PRT062607 30 mg/kg
Vehicle-treated arthritic miceDid not arrest clinical progression; joint inflammation partly reduced.[3]
Tofacitinib alone
Tofacitinib 20 mg/kg
Vehicle-treated arthritic miceStopped progression with some later clinical improvement.[3]
Combined PRT062607 and tofacitinib
PRT062607 30 mg/kg + tofacitinib 20 mg/kg
Vehicle and each single inhibitorGreater clinical/histological improvement; structural protection was a combination effect.[3]
PRT062607 alone
Model: Male DBA/1 mice with G6PI-induced chronic arthritis following regulatory T-cell depletion; Figure 2 caption reports 3–7 mice/group.
Reported limits: Author-reported free-amine-corrected doses; no conversion applied.
Tofacitinib alone
Model: Male DBA/1 mice with G6PI-induced chronic arthritis following regulatory T-cell depletion; Figure 2 caption reports 3–7 mice/group.
Reported limits: Author-reported free-amine-corrected doses; no conversion applied.
Combined PRT062607 and tofacitinib
Model: Male DBA/1 mice with G6PI-induced chronic arthritis following regulatory T-cell depletion; Figure 2 caption reports 3–7 mice/group.
Reported limits: Author-reported free-amine-corrected doses; no conversion applied.
Methods and source locations

Compound reported in the paper: P505-15 (PRT062607); Compound label in the paper: Literature material

Animal results for the reported PRT062607 material and author-reported dose basis, without validation of an Adooq lot.

Figure 2A–B, G–H and caption; Methods: Induction and scoring of arthritis, Treatments, Sample collection, Statistical analysis; Results: Dual JAK + SYK inhibition ameliorates chronic and severe G6PI-induced arthritis

Clinical arthritis progression after treatment of established disease: Figure 2A–B; mean + SEM; vehicle, JAKi, SYKi, dual and prednisolone comparators — Figure 2A–B, G–H and caption; Methods: Induction and scoring of arthritis, Treatments, Sample collection, Statistical analysis; Results: Dual JAK + SYK inhibition ameliorates chronic and severe G6PI-induced arthritis

Tarsal joint inflammation and structural damage: Figure 2G–H; mean + SEM; *p <0.05 versus vehicle per caption — Figure 2A–B, G–H and caption; Methods: Induction and scoring of arthritis, Treatments, Sample collection, Statistical analysis; Results: Dual JAK + SYK inhibition ameliorates chronic and severe G6PI-induced arthritis

PRT062607 alone · Figure 2A–B, G–H and caption; Methods: Induction and scoring of arthritis, Treatments, Sample collection, Statistical analysis; Results: Dual JAK + SYK inhibition ameliorates chronic and severe G6PI-induced arthritis

Tofacitinib alone · Figure 2A–B, G–H and caption; Methods: Induction and scoring of arthritis, Treatments, Sample collection, Statistical analysis; Results: Dual JAK + SYK inhibition ameliorates chronic and severe G6PI-induced arthritis

Combined PRT062607 and tofacitinib · Figure 2A–B, G–H and caption; Methods: Induction and scoring of arthritis, Treatments, Sample collection, Statistical analysis; Results: Dual JAK + SYK inhibition ameliorates chronic and severe G6PI-induced arthritis

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 1370261-96-3
Applications Syk inhibitor
Formula C19H23N9O
Molecular Weight 393.45
Synonyms PRT062607; BIIB057
SMILES
C1CC[C@H]([C@H](C1)N)NC2=NC=C(C(=N2)NC3=CC(=CC=C3)N4N=CC=N4)C(=O)N

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 85 mg/mL (197.71 mM)
Water 85 mg/mL (197.71 mM)
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
28 mg/mL
Vehicle
Saline

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Research References

  1. [1] Spurgeon SE, Coffey G, Fletcher LB, et al. The selective SYK inhibitor P505-15 (PRT062607) inhibits B cell signaling and function in vitro and in vivo and augments the activity of fludarabine in chronic lymphocytic leukemia The Journal of pharmacology and experimental therapeutics (2013). PMID: 23220742 DOI: 10.1124/jpet.112.200832 Source material
  2. [2] Coffey G, Betz A, Graf J, et al. Methotrexate and a spleen tyrosine kinase inhibitor cooperate to inhibit responses to peripheral blood B cells in rheumatoid arthritis Pharmacology research & perspectives (2013). PMID: 25505569 DOI: 10.1002/prp2.16 Source material
  3. [3] Llop-Guevara A, Porras M, Cendón C, et al. Simultaneous inhibition of JAK and SYK kinases ameliorates chronic and destructive arthritis in mice Arthritis research & therapy (2015). PMID: 26653844 DOI: 10.1186/s13075-015-0866-0 Source material

Publications

1 publication citing this product

  1. Li T, .et al. , Oncogene, 2018, Nov;37(47):6180-6194 PMID: 30013190

Added to your cart

View Cart Checkout
Loading...